Medy-Tox Inc. (KOSDAQ:086900)
South Korea
· Delayed Price · Currency is KRW 123,800
+3,100 (2.57%)
Mar 10, 2026, 10:00 AM KST
Medy-Tox Revenue
Medy-Tox had revenue of 61.02B KRW in the quarter ending September 30, 2025, with 13.30% growth. This brings the company's revenue in the last twelve months to 241.80B, up 0.14% year-over-year. In the year 2024, Medy-Tox had annual revenue of 228.62B with 3.39% growth.
Revenue (ttm)
241.80B
Revenue Growth
+0.14%
P/S Ratio
3.50
Revenue / Employee
336.76M
Employees
718
Market Cap
847.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 228.62B | 7.50B | 3.39% |
| Dec 31, 2023 | 221.12B | 26.02B | 13.34% |
| Dec 31, 2022 | 195.10B | 10.23B | 5.53% |
| Dec 31, 2021 | 184.87B | 44.04B | 31.27% |
| Dec 31, 2020 | 140.83B | -65.07B | -31.60% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharmicell | 23.94B |
| Onconic Therapeutics | 46.65B |
| MEDIPOST | 73.59B |
| GI Innovation | 338.09M |
| Green Cross Holdings | 2,397.09B |
| SillaJen | 7.84B |
| Genomictree | 3.76B |
| BINEX | 165.64B |